Do analysts prefer XGN or VMD?

Exagen presently has a consensus price target of $9.11, indicating a potential upside of 89.81%. Given Exagen's stronger consensus rating and higher possible upside, equities analysts clearly believe Exagen is more favorable than Viemed Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Viemed Healthcare 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, XGN or VMD?

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.74 -$19.95M -$0.89 N/A Viemed Healthcare $270.28M 1.71 $14.93M $0.37 32.62

Which has higher valuation and earnings, XGN or AUNA?

Auna has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.74 -$19.95M -$0.89 N/A Auna $1.23B 0.31 $27.39M $0.26 19.94

Is XGN or AUNA more profitable?

Auna has a net margin of 1.53% compared to Exagen's net margin of -29.49%. Auna's return on equity of 16.25% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% Auna 1.53% 16.25% 4.03%

Which has higher valuation and earnings, XGN or SBC?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.74 -$19.95M -$0.89 N/A SBC Medical Group $173.61M 1.75 $50.99M $0.39 7.59

Is XGN or SBC more profitable?

SBC Medical Group has a net margin of 24.09% compared to Exagen's net margin of -29.49%. SBC Medical Group's return on equity of 15.90% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% SBC Medical Group 24.09% 15.90% 11.61%

Which has higher valuation & earnings, BDSX or XGN?

Exagen has lower revenue, but higher earnings than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 2.38 -$35.26M -$4.06 N/A Exagen $66.57M 1.74 -$19.95M -$0.89 N/A

Is BDSX or XGN more profitable?

Exagen has a net margin of -29.49% compared to Biodesix's net margin of -33.26%. Exagen's return on equity of -94.37% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -33.26% -2,101.40% -35.65% Exagen -29.49% -94.37% -28.96%

Exagen (XGN) Competitors

$4.80 +0.40 (+9.09%)

Closing price 04:00 PM Eastern

Extended Trading

$4.83 +0.03 (+0.65%)

As of 07:50 PM Eastern

Compare

XGN vs. VMD, AUNA, SBC, AIRS, and BDSX

Should you buy Exagen stock or one of its competitors? MarketBeat compares Exagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exagen include Viemed Healthcare (VMD), Auna (AUNA), SBC Medical Group (SBC), AirSculpt Technologies (AIRS), and Biodesix (BDSX). These companies are all part of the "healthcare" industry.

How does Exagen compare to Viemed Healthcare?

Exagen (NASDAQ:XGN) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Viemed Healthcare has a net margin of 5.20% compared to Exagen's net margin of -29.49%. Viemed Healthcare's return on equity of 10.52% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Viemed Healthcare	5.20%	10.52%	7.60%

75.3% of Exagen shares are held by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 20.0% of Viemed Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Exagen's average media sentiment score of 0.00 equaled Viemed Healthcare'saverage media sentiment score.

Company	Overall Sentiment
Exagen	Neutral
Viemed Healthcare	Neutral

Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.74	-$19.95M	-$0.89	N/A
Viemed Healthcare	$270.28M	1.71	$14.93M	$0.37	32.62

Exagen presently has a consensus price target of $9.11, indicating a potential upside of 89.81%. Given Exagen's stronger consensus rating and higher possible upside, equities analysts clearly believe Exagen is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Viemed Healthcare beats Exagen on 8 of the 15 factors compared between the two stocks.

How does Exagen compare to Auna?

Exagen (NASDAQ:XGN) and Auna (NYSE:AUNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Auna has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.74	-$19.95M	-$0.89	N/A
Auna	$1.23B	0.31	$27.39M	$0.26	19.94

Exagen has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Auna has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Exagen currently has a consensus price target of $9.11, indicating a potential upside of 89.81%. Auna has a consensus price target of $6.97, indicating a potential upside of 34.36%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Exagen is more favorable than Auna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Auna	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Auna has a net margin of 1.53% compared to Exagen's net margin of -29.49%. Auna's return on equity of 16.25% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Auna	1.53%	16.25%	4.03%

75.3% of Exagen shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Auna had 3 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Auna and 0 mentions for Exagen. Auna's average media sentiment score of 0.12 beat Exagen's score of 0.00 indicating that Auna is being referred to more favorably in the news media.

Company	Overall Sentiment
Exagen	Neutral
Auna	Neutral

Summary

Auna beats Exagen on 9 of the 16 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

Exagen (NASDAQ:XGN) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

In the previous week, Exagen's average media sentiment score of 0.00 equaled SBC Medical Group'saverage media sentiment score.

Company	Overall Sentiment
Exagen	Neutral
SBC Medical Group	Neutral

75.3% of Exagen shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Exagen has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.74	-$19.95M	-$0.89	N/A
SBC Medical Group	$173.61M	1.75	$50.99M	$0.39	7.59

Exagen currently has a consensus price target of $9.11, indicating a potential upside of 89.81%. SBC Medical Group has a consensus price target of $8.50, indicating a potential upside of 187.16%. Given SBC Medical Group's higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SBC Medical Group has a net margin of 24.09% compared to Exagen's net margin of -29.49%. SBC Medical Group's return on equity of 15.90% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
SBC Medical Group	24.09%	15.90%	11.61%

Summary

SBC Medical Group beats Exagen on 10 of the 15 factors compared between the two stocks.

How does Exagen compare to AirSculpt Technologies?

Exagen (NASDAQ:XGN) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

AirSculpt Technologies has a net margin of -7.39% compared to Exagen's net margin of -29.49%. AirSculpt Technologies' return on equity of -4.98% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
AirSculpt Technologies	-7.39%	-4.98%	-2.36%

In the previous week, Exagen's average media sentiment score of 0.00 equaled AirSculpt Technologies'average media sentiment score.

Company	Overall Sentiment
Exagen	Neutral
AirSculpt Technologies	Neutral

Exagen presently has a consensus target price of $9.11, suggesting a potential upside of 89.81%. AirSculpt Technologies has a consensus target price of $4.50, suggesting a potential upside of 6.64%. Given Exagen's stronger consensus rating and higher probable upside, research analysts clearly believe Exagen is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

AirSculpt Technologies has higher revenue and earnings than Exagen. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.74	-$19.95M	-$0.89	N/A
AirSculpt Technologies	$151.82M	1.96	-$11.67M	-$0.17	N/A

Exagen has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market.

75.3% of Exagen shares are held by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 44.6% of AirSculpt Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

AirSculpt Technologies beats Exagen on 10 of the 15 factors compared between the two stocks.

How does Exagen compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Exagen has lower revenue, but higher earnings than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	2.38	-$35.26M	-$4.06	N/A
Exagen	$66.57M	1.74	-$19.95M	-$0.89	N/A

21.0% of Biodesix shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biodesix has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Exagen has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market.

Exagen has a net margin of -29.49% compared to Biodesix's net margin of -33.26%. Exagen's return on equity of -94.37% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Exagen	-29.49%	-94.37%	-28.96%

Biodesix presently has a consensus price target of $28.33, suggesting a potential upside of 39.30%. Exagen has a consensus price target of $9.11, suggesting a potential upside of 89.81%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Biodesix's average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.

Company	Overall Sentiment
Biodesix	Neutral
Exagen	Neutral

Summary

Exagen beats Biodesix on 10 of the 14 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$115.97M	$8.54B	$6.95B	$12.44B
Dividend Yield	N/A	2.45%	2.67%	6.51%
P/E Ratio	-5.39	16.49	27.22	24.45
Price / Sales	1.74	5.99	532.23	95.06
Price / Cash	N/A	18.40	29.65	49.26
Price / Book	6.23	3.63	10.97	6.42
Net Income	-$19.95M	$226.17M	$3.56B	$335.85M
7 Day Performance	3.23%	2.73%	1.77%	-0.48%
1 Month Performance	11.89%	0.01%	6.65%	3.39%
1 Year Performance	-31.03%	2.04%	36.06%	24.97%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	3.631 of 5 stars	$4.80 +9.1%	$9.11 +89.8%	-34.7%	$115.97M	$66.57M	N/A	220
VMD Viemed Healthcare	2.0875 of 5 stars	$11.40 +0.1%	N/A	+69.3%	$436.66M	$270.28M	30.81	1,382
AUNA Auna	4.9303 of 5 stars	$5.16 +2.9%	$6.97 +35.1%	-16.1%	$370.80M	$1.23B	19.83	15,254	News Coverage Analyst Downgrade
SBC SBC Medical Group	3.5985 of 5 stars	$3.08 -2.2%	$8.50 +176.0%	-31.4%	$323.12M	$173.61M	7.90	N/A	Positive News
AIRS AirSculpt Technologies	1.3163 of 5 stars	$4.50 -0.4%	$4.50	-16.2%	$318.87M	$151.82M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. VMD, AUNA, SBC, AIRS, and BDSX

How does Exagen compare to Viemed Healthcare?

Summary

How does Exagen compare to Auna?

Summary

How does Exagen compare to SBC Medical Group?

Summary

How does Exagen compare to AirSculpt Technologies?

Summary

How does Exagen compare to Biodesix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. VMD, AUNA, SBC, AIRS, and BDSX

How does Exagen compare to Viemed Healthcare?

Is XGN or VMD more profitable?

Do institutionals & insiders believe in XGN or VMD?

Does the media refer more to XGN or VMD?

Which has more risk & volatility, XGN or VMD?

Which has preferable earnings and valuation, XGN or VMD?

Do analysts prefer XGN or VMD?

Summary

How does Exagen compare to Auna?

Which has higher valuation and earnings, XGN or AUNA?

Which has more volatility and risk, XGN or AUNA?

Do analysts recommend XGN or AUNA?

Is XGN or AUNA more profitable?

Do insiders & institutionals have more ownership in XGN or AUNA?

Does the media favor XGN or AUNA?

Summary

How does Exagen compare to SBC Medical Group?

Does the media favor XGN or SBC?

Do insiders & institutionals have more ownership in XGN or SBC?

Which has more volatility and risk, XGN or SBC?

Which has higher valuation and earnings, XGN or SBC?

Do analysts recommend XGN or SBC?

Is XGN or SBC more profitable?

Summary

How does Exagen compare to AirSculpt Technologies?

Is XGN or AIRS more profitable?

Does the media refer more to XGN or AIRS?

Do analysts recommend XGN or AIRS?

Which has better earnings & valuation, XGN or AIRS?

Which has more risk and volatility, XGN or AIRS?

Do insiders & institutionals hold more shares of XGN or AIRS?

Summary

How does Exagen compare to Biodesix?

Which has higher valuation & earnings, BDSX or XGN?

Do institutionals and insiders believe in BDSX or XGN?

Which has more volatility and risk, BDSX or XGN?

Is BDSX or XGN more profitable?

Do analysts recommend BDSX or XGN?

Does the media refer more to BDSX or XGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools